{"name":"Talphera, Inc","slug":"talphera-inc","ticker":"","exchange":"","domain":"","description":"Talphera, Inc is a biopharmaceutical company focused on the development of innovative treatments for pain management. The company has a pipeline of 23 drugs, with several in early and late-stage clinical trials, including Zalviso™ 15 mcg, which is in Phase 3.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":475000,"revenueGrowth":-21.9,"grossMargin":0,"rdSpend":6033000,"netIncome":-14290000,"cash":5894000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo Sufentanil NanoTab PCA System","genericName":"Placebo Sufentanil NanoTab PCA System","slug":"placebo-sufentanil-nanotab-pca-system","indication":"Acute pain management in opioid-tolerant patients via patient-controlled analgesia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"morphine IV PCA","genericName":"morphine IV PCA","slug":"morphine-iv-pca","indication":"Severe pain","status":"phase_3"}]}],"pipeline":[{"name":"Placebo Sufentanil NanoTab PCA System","genericName":"Placebo Sufentanil NanoTab PCA System","slug":"placebo-sufentanil-nanotab-pca-system","phase":"phase_3","mechanism":"Sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to provide rapid pain relief via patient-controlled analgesia.","indications":["Acute pain management in opioid-tolerant patients via patient-controlled analgesia"],"catalyst":""},{"name":"morphine IV PCA","genericName":"morphine IV PCA","slug":"morphine-iv-pca","phase":"phase_3","mechanism":"Morphine binds to opioid receptors in the brain and spinal cord, producing analgesia and altering mood.","indications":["Severe pain","Cancer pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPMXkycDRjeU9tdUctbFc0a1ZBclRVRE8tZ2hhczRscVBOR3dWbUdISkRaOXdoVVYweVNoMF9xTVpoUHhLaFM1QzFiR29XZUczWUVlNG15cE1fZk1TU1pTUFlJOF9iS2VPSVk2cC0xbzlUWGxzZFAtYTE0SDRuRFhILXZTMTlpVkJ6WnVzaXVOTjc2aXcwZ1BYTDIzSnZacUlQZ3BfMndOamNxdHMzcEhhaTJSc0ZBcXNRelB6NU5XR1J6MXFSdjZwckZmQVEzWG90Si1xUGVIc1lFSnpJZ05leUJ5MnlLSS1LcVliVklJaVpNSkVNUkotdzFRejJHN3ZTV1QzYlhBNmhHNGc3bDdQWXdLRDhhRmxvZ3ZhWEJKc25fU212ZzZXTU9mOXBydXM?oc=5","date":"2026-03-25","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOd0VmTlVCUS1LcWtMVkEyMXVBSWRWV0hqb0V4VG4zZC1ZTHljNUIxY0dZZUhjZlk4d1VVNFZKV0Rqb0lqV0VQTFpPaEZWX09iS1BQTV9kczJHMW9kM2lNWlRCNndCMmRudnQ3X0RfV05FT0Z2aVZrZ2s3Qk5fVzE1SGI2UExUNVRiVy1zbTZ3NWNLWk9nMUNYUlpzZlRlVWkyc0lCdzNIQWZNcUdWNURaRGlKMFV0ZTA5RDIwcGFieEJZMTNBQ0Z0MURWdnI?oc=5","date":"2026-03-25","type":"pipeline","source":"PR Newswire","summary":"Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 - PR Newswire","headline":"Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOdHJPLWRXVVFBT2dsOVd2V1hSOW9zQWZORlo1bDl5TnRWYXVXQVRmVVZucVRCUE02YUhuTFFKZ21zamVzdUlINnlIeExVMHpBTXFCd2ljLU0waU02UWdPOWY3LWdnM25uTFJ1TTd4ZU5xazVTNEp3ckg0bHpzaV9ZamswdGV6Z25RX25VM3BDV3MtaDJCRnZVXzJ2Rm1pRjFBQUlnZ1ZqNWFUNFc1Um80dWJKamE4UEpka2R5RzBEdFY5WUxDWEhJTl9WM2NYZU5kWmVVMXR2WkpVYS0wcjIyaFBEWlNlZEQ4NU42cjFPUWgybEdKYkJPcmlmTzNGY3l6?oc=5","date":"2026-03-24","type":"regulatory","source":"Minichart","summary":"Talphera, Inc. (Formerly AcelRx) 2025 Annual Report: Business Overview, Key Risks, and Regulatory Challenges in Specialty Pharmaceuticals - Minichart","headline":"Talphera, Inc. (Formerly AcelRx) 2025 Annual Report: Business Overview, Key Risks, and Regulatory Challenges in Specialt","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNMkk1bFlVZjdlakhxcUtaUEZxcV9ucTNYejRpTTRhTjF0YzR4d0hNaDNOeE05QkozM2FZX0E0a3Y0ZmlnYWxuLTlBeDg4dW1iTkx4QldMWnBDNHdsRlhBN28xcjNnTzJrSWM0WXROTkh6SjNnbHBwbXNkcDVJdXBfc1VkaTltMWdTdW9Oa0E4SHh2NnFZYnVKUTlXMWYzNEJrNDljdlFUTnhPenZTVTlJUXl1ZGp6T3BsSU03cVpiNU5hdUpJLWlrbjhlelNaQWJ6NEVfZG12NW4tTEtRVlAtS2F0TjEtb0ptaFRaUFY1ZXpxQWg3bG0tNzdQS2d5UEF3OWJj?oc=5","date":"2026-03-04","type":"pipeline","source":"The Globe and Mail","summary":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail","headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPWVgyeWI0WmtDTFdzeHZzSHNuRXNYMVBjVlBVTTdJYWtYdVlKbVpHcHpqczBBRHJDOGpqc0dSMmJ6Ny1udnYtcWFFb00yWm5hVUN5US10XzN5SWNhUUtTY1c1NHhaSXpzbEwtSnI3Zl9Cc2FlX1RZWm9lS0hNZ05FQVgxVHZlMWJ6TFRyNHkxdXVnUmRzQ0VBYlJSX2d2MGRuNTRYZ1pMcklOY0RBYzJzckZqWTgxSkYtZmJORzBKYTBWNDktMDludHByY1NhM2xwa2NzSjlIQUVjZw?oc=5","date":"2026-03-02","type":"trial","source":"PR Newswire","summary":"Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial - PR Newswire","headline":"Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOc05wWDR0SU9sclRFMFJlM25fQjdFSzY1Z1Z2RWFsVy1qa0lxdFJJb09lZHd1bGJ2WHFxMWhUcHlxZW9kdEUyazZEQVpqT0U2Tk1kdWhsVlVVRi1WNDYyR2NOMVZ1ZFNhYUxpbkRIYUxiaUJoV1ZnREdFNkN2NnhYTlJ4RXNkZUp4cG5BY0FYZ0VfNVpUS2ZIbElkZjFXbjBWM2lXbQ?oc=5","date":"2026-02-17","type":"pipeline","source":"GuruFocus","summary":"Rosalind Advisors, Inc. Expands Stake in Talphera Inc. - GuruFocus","headline":"Rosalind Advisors, Inc. Expands Stake in Talphera Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQaUNPUTUwVHR5cVMwTVQtSWlwVmJPX1lESmFJcEVtQXVMdmF3T1ozYnRWd01RdTBBckhFUUlqS29SVk9RNXNNcHZuOVZmZEhvQXNEM3l0Mk44WDRYaXB6dlBJSUNramVkNTJjbU9ocDE0RUt5VHpuS2tZZGxUN1JnNnM1NnFkT2NpLTFicy1fUy1sWncxMm9qcGJPbWhrRzhPME1UZ05SR1FoUTc0Y2ZGSmJCUlNzMW4xTjJZa3hkOFdlam9YckhTaFh3ZVVGeEw3S2lwRzRhNDU?oc=5","date":"2025-11-12","type":"earnings","source":"PR Newswire","summary":"Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire","headline":"Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOYVE1V3Z2NjVvb09iaFY0MWlrNWJuNVpmNWd0cV9VY1E2cXRESThwcHBYTXM4akhaZGJHQUhpMUM0cU84bUNRdFVWZHg0VTYtaUVudU8yQmkzYWZScDJfSGhiNGp2NUhBcWl1Tnp4Ul9mZGQta3A0eURWVlZtMjhuVFFkYnFMdWlRc2hsTGduZ3h2Tm9CaUF1SHYtYVVQcEtTTWRLbGppeGIwcFNneVR6d05KZ3MzMU5BNFd0MFM2dW1IWE5Lcmc?oc=5","date":"2025-10-21","type":"pipeline","source":"PR Newswire","summary":"Talphera Announces the Appointment of Joe Todisco to Board of Directors - PR Newswire","headline":"Talphera Announces the Appointment of Joe Todisco to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRU1jaU9JNVk5TUxjOEFEbXpMa0xmcTFZc1MtdEZvQmstZ3ZQLW1xTjlncC1zdFRsWExvOE1pZXp5LVlNd3VwOGxZamlVWE40NmcyTzZrUW43OUtTM0czMjJleHNGZ2twYVh5ZGhGUTJZVk45WHc0Mk1NbG1vTnc2MXpXajVJaDZpczUwb1pYaExkc0wzVE9ielVDT3dBNFZyM0VCekw0SlFidlJQbnZsSWtGaUV6RHJaX0EwSk51azJucUFqRWJqLW04b2VjM1NzX0RTVVc3VQ?oc=5","date":"2025-10-17","type":"pipeline","source":"The Globe and Mail","summary":"Talphera Appoints Joseph Todisco to Board of Directors - The Globe and Mail","headline":"Talphera Appoints Joseph Todisco to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPU3lWWHZXWnhYbEp3bUQ4WFNpVFZhXzIwOW5yN092YzQta0cwRFRyVWdYNUVWX2dXbW1pSlJsWGpBRWFnbWZ6SDlUVnBnNTc4dFQ3aGpKR2RxaTctYXg1ei1raVpFY3FTSkFuVS00OUp3RjAzS2lWbFBIZ1d2em9RaGdLX1BENTdUZHZpaDNqVlBWc0tlTGxNNHpreDk5VkwzZGRoRWJKOUtUSmpOTjdRMTJOenZqWVBYNl9zeFVWN2phTnd3Z01qYUpxWmpXVGFYN3VhWDFGdEhodHNiVFphTFJsN3I?oc=5","date":"2025-08-25","type":"trial","source":"PR Newswire","summary":"Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial - PR Newswire","headline":"Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOMVVtVl9GMDQtQzdSZ2cwN2VrN2FfQkJRM09KaXE0ZGlJektING1LR2pnYWs1ZGhpYWt4ZmhLSEJjRzBNdEdaODNGdnZ0d0VsdG11ZVpyWHFDZldsQXVGWHBtSHEtSkppWERBSE5Wb2pVOTdkY3JoWkZRMjFPMUxfXzZZVE9qbjVjRTY3RjQ3cC13NllKYTBzOVh3Yko2UWp3?oc=5","date":"2024-01-10","type":"pipeline","source":"Fierce Pharma","summary":"AcelRx becomes Talphera, adopting new name to reflect pain pivot - Fierce Pharma","headline":"AcelRx becomes Talphera, adopting new name to reflect pain pivot","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":475000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":475000,"period":"2019-12-31"},{"value":608000,"period":"2019-09-30"},{"value":941000,"period":"2019-06-30"},{"value":265000,"period":"2019-03-31"},{"value":2151000,"period":"2018-12-31"},{"value":377000,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6033000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-14290000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":5894000,"cashHistory":[],"totalAssets":29719000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}